Jared Roach, MD, PhD, Institute for Systems Biology, Seattle, Washington, discusses the rationale for the COCOA trial: a multimodal lifestyle intervention study aimed at treating Alzheimer’s disease (AD). For over a decade, leaders in the field have thought that using many types of interventions in parallel could be the best way to treat AD. COCOA aimed to investigate if personalized, multimodal lifestyle and clinical interventions could ameliorate cognitive decline in those with early AD, as well as to identify the molecular pathways through which these interventions act, in order to improve interventions and inform future trials. Coached interventions were tailored based on personal, clinical, and molecular data and could include lifestyle interventions and cognitive training. Over 18 months, the results showed a 60% reduction in cognitive decline in the intervention group, compared to those receiving standard of care. This highlights the need for clinicians and clinical guidelines to emphasize the importance of prioritizing a multimodal lifestyle intervention and using pharmaceutical drugs as an addition to this. This interview took place at the Clinical Trials on Alzheimer’s Disease congress 2022 in San Francisco.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.